Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation (Nasdaq: XOMA) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its royalty aggregation business, capital structure, and transaction activity. On this page, you can review XOMA Royalty’s SEC filings alongside AI-powered summaries that help explain the key points in accessible language.
For investors analyzing XOMA Royalty, Form 10-K annual reports and Form 10-Q quarterly reports provide detail on royalty and milestone receipts, portfolio composition, risk factors, and accounting for acquired economic interests. Form 8-K current reports document material events such as the completion of acquisitions of HilleVax, LAVA Therapeutics, and Mural Oncology, entry into at-the-market sales agreements for common and preferred stock, and announcements of financial results.
XOMA Royalty’s filings also describe its listed securities, including common stock (XOMA) and preferred instruments such as 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) and depositary shares representing 8.375% Series B Cumulative Perpetual Preferred Stock (XOMAO). Related registration statements and prospectus supplements outline how proceeds from these offerings may be used to acquire additional potential royalty and milestone revenue streams, fund preferred dividends, and support general corporate purposes.
In addition, Form 4 insider transaction reports and proxy materials can provide insight into equity ownership and governance, while exhibits to 8-K filings include key agreements such as merger agreements, share purchase agreements, contingent value rights agreements, and sales agreements. Stock Titan’s interface enhances these filings with AI-generated highlights that point out important terms, transaction structures, and potential implications for XOMA Royalty’s royalty and milestone portfolio, helping readers navigate complex legal and financial disclosures more efficiently.
Montano Maricel Perea reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp reported that Chief Legal Officer Maricel Perea Montano received new equity awards. She was granted 26,289 restricted stock units payable in common stock, which vest in four equal annual installments starting on March 11, 2026, contingent on continued service.
She also received 40,444 performance stock units, each representing a right to one share of common stock. These performance units vest only if the common stock reaches a specified price per share and she remains in service, aligning a portion of her compensation with long-term share performance.
XOMA ROYALTY CORPORATION ownership update: FMR LLC reports beneficial ownership of 1,268,506.14 shares of common stock, representing 10.2% of the class as of 02/27/2026. The filing also notes that Fidelity Contrafund held 773,332 shares, or 6.2%, as of the same date.
The schedule is an amendment (No. 5) and identifies filings and powers of attorney authorizing the submission; Exhibit 99 and related exhibits are referenced for subsidiary and agreement details.
XOMA Royalty Corporation furnished an updated corporate presentation outlining its royalty aggregation business model, portfolio, and preliminary 2025 financial data. The company focuses on acquiring early- to mid‑stage biotech royalty and milestone rights and highlights a diversified portfolio exceeding 100 assets, with more than $140M in milestones received since 2017 and over $2B in potential future milestones.
The presentation’s preliminary 2025 update shows $49–50M in cash received from royalties and milestones and about $133M of cash, cash equivalents and restricted cash as of December 31, 2025. XOMA repurchased and retired 648,048 common shares during 2025 for $16M, with 11,888,489 common shares outstanding as of February 27, 2026. General and administrative expenses for 2025 include roughly $1M tied to ongoing litigation with Janssen Biotech regarding use of XOMA intellectual property, and the company notes that the outcome and any potential recovery are uncertain.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed an amended Schedule 13G reporting significant ownership in XOMA Royalty Corp common stock. They report beneficial ownership of 1,702,545 shares, representing 13.7% of the class, with voting and dispositive power shared through affiliated entities.
The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of XOMA Royalty Corp.
XOMA Royalty Corporation has completed its acquisition of Generation Bio Co. through a tender offer followed by a merger. XOMA Royalty’s subsidiary first purchased Generation Bio common shares at $4.2913 per share in cash plus one contingent value right (CVR) per share, then merged the subsidiary into Generation Bio.
As of the tender expiration on February 6, 2026, holders had validly tendered 4,722,533 shares, representing about 70% of Generation Bio’s outstanding stock, satisfying the minimum tender condition. Remaining eligible shares were converted into the same cash-and-CVR package, and Generation Bio is now a wholly owned subsidiary of XOMA Royalty.
XOMA Royalty Corporation and its subsidiary XRA 7 Corp. have completed their tender offer and merger to acquire Generation Bio Co. for $4.2913 in cash plus one contingent value right (CVR) per share. The offer expired on February 6, 2026, with about 4,722,533 shares, or roughly 70% of the company, validly tendered. All tendered shares have been accepted and paid for, and a merger under Delaware law closed on February 9, 2026, making Generation Bio a wholly owned subsidiary of XOMA. Remaining untendered shares (with limited exceptions) were converted into the right to receive the same cash-and-CVR consideration. Generation Bio’s stock has stopped trading on Nasdaq, and the company is moving to delist and deregister its shares and suspend its SEC reporting obligations.
XOMA Royalty Corporation filed an amended report to give more detail on the legacy assets it acquired with LAVA Therapeutics. These include EGFRd2 (PF-8046052), outlicensed to Pfizer for cancers, and JNJ-89853413, outlicensed to Janssen Biotech for acute myeloid leukemia, both in early clinical trials with Pfizer and Janssen responsible for development and commercialization.
XOMA also acquired LAVA-1266 but does not plan further development and is seeking a sale or other disposition. Former LAVA shareholders received contingent value rights (CVRs) tied to any future monetization of these assets, with 75% of net proceeds payable through the CVRs. XOMA and LAVA previously estimated the CVR value at $0.00 because of the high uncertainty around early-stage oncology programs and limited prospects for LAVA-1266.
XOMA Royalty Corporation and its subsidiary XRA 7 Corp. have filed Amendment No. 2 to their tender offer for all outstanding shares of Generation Bio Co. at $4.2913 in cash plus one contingent value right (CVR) per share. Each CVR may entitle holders to future cash payments if specified events occur under a CVR Agreement. The Buyer Entities state they did not obtain an independent valuation or material non-public analysis of potential CVR proceeds and are relying on Generation Bio’s own estimate. They emphasize that they cannot predict whether any CVR proceeds will ever be paid, or in what amount or timing. The amendment explains that any Net Cash Shortfall can only be recovered from CVR proceeds that would otherwise become payable, and CVR holders will only learn of such a shortfall if it reduces a payment. It also confirms that all offer conditions are for the Buyer Entities’ benefit, that the minimum tender and termination conditions cannot be waived, and that if any condition is triggered the Buyer Entities will promptly inform stockholders whether they intend to assert or waive it.
XOMA Royalty Corporation is making a leadership change in its finance organization. Effective January 12, 2026, the board appointed Jeffrey Trigilio as Chief Financial Officer, succeeding Thomas Burns, who stepped down from his role on the same date.
Mr. Trigilio will receive an annual base salary of $515,000 and is eligible for a target annual cash bonus equal to 40% of base salary. His compensation package includes an initial grant of 30,000 performance units that vest based on stock price hurdles over a period ending on the earlier of May 18, 2026 or the 2026 annual stockholder meeting, plus a 2026 annual equity grant valued at 180,000 times the closing price of XOMA common stock on the effective date.
The employment agreement provides severance and change-of-control protections, including up to 1.5 times base salary and target bonus, extended health benefits, outplacement services, and accelerated equity vesting in certain termination scenarios. Mr. Burns will receive severance under his existing agreement, acceleration of certain performance stock units, and a consulting role for three months at $16,000 per month to support transition.
XOMA Royalty Corp reported an equity award to its Chief Financial Officer, Jeffrey Trigilio. On 01/12/2026, he was granted 30,000 Performance Stock Units (PSUs) at an exercise price of $0 per unit, recorded as a derivative security held directly.
Each PSU represents a contingent right to receive one share of XOMA common stock. The PSUs vest only if XOMA’s common stock reaches a specified price per share, tying the potential stock delivery to future share-price performance. After this grant, Trigilio beneficially owned 30,000 PSUs.